Balanced news tone
News Sentiment
BIIB sentiment intelligence
Biogen Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-8.1% over one week, -1.0% over four weeks, trend active, and near fair-value range.
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 14:51
- Source
- Yahoo! Finance Canada
Biogen's incoming legal chief has 20 years in biotech leadership
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 12:15
- Source
- Stock Titan
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 10:38
- Source
- Clinical Trials Arena
Biogen Dips As Questions Weigh On Alzheimer's 'Breakthrough'
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 20:13
- Source
- Investor's Business Daily
Biogen’s Alzheimer’s Drug Leaves Questions Unanswered, and That’s a Problem
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:09
- Source
- Barron's
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:00
- Source
- Fierce Biotech
Biogen stock falls 8% on Alzheimer's drug diranersen trial data
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 14 Jul 2026 17:42
- Source
- qz.com
Biogen slides as investors reassess Alzheimer’s data and earnings overhang
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 14:51
- Source
- Quiver Quantitative
How Investors Are Reacting To Biogen (BIIB) At-Home LEQEMBI Autoinjector Approval
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 14:14
- Source
- Market source
Biogen Shares Rise After Positive Phase 2 Alzheimer’s Trial Results (BIIB)
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 14 Jul 2026 13:48
- Source
- Market source
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
- Tone
- Positive 84/100
- Event
- Analyst action
- Published
- 13 Jul 2026 18:32
- Source
- Barron's
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Market source
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 29 Jun 2026 07:00
- Source
- Market source
Why Biogen (BIIB) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Biogen stock price forecast: $174.41 support comes into view as BIIB slips 1.94%
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 19 Jun 2026 07:00
- Source
- Traders Union
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Market source
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Biogen
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Mar 2026 12:32
- Source
- Biogen
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2025 08:00
- Source
- Biogen
Biogen to Acquire Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2023 07:00
- Source
- Biogen
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 09 Jun 2023 07:00
- Source
- Biogen
Biogen Inc.: Target Price Consensus and Analysts Recommendations | BIIB | US09062X1037
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 18 Aug 2020 17:42
- Source
- marketscreener.com
Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 12 Jun 2019 10:45
- Source
- Biogen
Biogen Inc (BIIB) Stock Price, Trades & News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Apr 2019 16:19
- Source
- GuruFocus
Biogen Completes Separation of Global Hemophilia Business, Bioverativ
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Feb 2017 08:00
- Source
- Biogen